Bulk Manufacturer of Controlled Substances Application: Nanosyn Inc., 55689 [2020-19868]
Download as PDF
55689
Federal Register / Vol. 85, No. 175 / Wednesday, September 9, 2020 / Notices
BPI in the preliminary phase of the
investigation need not reapply for such
access. A separate service list will be
maintained by the Secretary for those
parties authorized to receive BPI under
the APO.
Staff report.—The prehearing staff
report in the final phase of this
investigation will be placed in the
nonpublic record on December 22, 2020,
and a public version will be issued
thereafter, pursuant to § 207.22 of the
Commission’s rules.
Hearing.—The Commission will hold
a hearing in connection with the final
phase of this investigation beginning at
9:30 a.m. on Tuesday, January 12, 2021.
Information about the place and form of
the hearing, including about how to
participate in and/or view the hearing,
will be posted on the Commission’s
website at https://www.usitc.gov/
calendarpad/calendar.html. Interested
parties should check the Commission’s
website periodically for updates.
Requests to appear at the hearing
should be filed in writing with the
Secretary to the Commission on or
before January 7, 2021. A nonparty who
has testimony that may aid the
Commission’s deliberations may request
permission to present a short statement
at the hearing. All parties and
nonparties desiring to appear at the
hearing and make oral presentations
should participate in a prehearing
conference to be held on January 8,
2021, if deemed necessary. Oral
testimony and written materials to be
submitted at the public hearing are
governed by §§ 201.6(b)(2), 201.13(f),
and 207.24 of the Commission’s rules.
Parties must submit any request to
present a portion of their hearing
testimony in camera no later than 7
business days prior to the date of the
hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of § 207.23 of the
Commission’s rules; the deadline for
filing is January 5, 2021. Parties may
also file written testimony in connection
with their presentation at the hearing, as
provided in § 207.24 of the
Commission’s rules, and posthearing
briefs, which must conform with the
provisions of section 207.25 of the
Commission’s rules. The deadline for
filing posthearing briefs is January 20,
2021. In addition, any person who has
not entered an appearance as a party to
the investigation may submit a written
statement of information pertinent to
the subject of the investigation,
including statements of support or
opposition to the petition, on or before
VerDate Sep<11>2014
17:06 Sep 08, 2020
Jkt 250001
January 20, 2021. On February 3, 2021,
the Commission will make available to
parties all information on which they
have not had an opportunity to
comment. Parties may submit final
comments on this information on or
before February 5, 2021, but such final
comments must not contain new factual
information and must otherwise comply
with § 207.30 of the Commission’s rules.
All written submissions must conform
with the provisions of § 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of §§ 201.6, 207.3, and
207.7 of the Commission’s rules. The
Commission’s Handbook on Filing
Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
Additional written submissions to the
Commission, including requests
pursuant to § 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with §§ 201.16(c) and
207.3 of the Commission’s rules, each
document filed by a party to the
investigation must be served on all other
parties to the investigation (as identified
by either the public or BPI service list),
and a certificate of service must be
timely filed. The Secretary will not
accept a document for filing without a
certificate of service.
Authority: This investigation is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to § 207.21 of the Commission’s
rules.
By order of the Commission.
Issued: September 2, 2020.
Lisa Barton,
Secretary to the Commission.
Drug Enforcement Administration
[Docket No. DEA–704]
Bulk Manufacturer of Controlled
Substances Application: Nanosyn Inc.
Frm 00054
Fmt 4703
Sfmt 4703
Controlled substance
Oxymorphone ................
Fentanyl .........................
Drug
code
9652
9801
Schedule
II
II
The company is a contract
manufacturer. At the request of the
company’s customers, it manufactures
derivatives of controlled substances in
bulk form.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–19868 Filed 9–8–20; 8:45 am]
BILLING CODE P
[OMB Number 1117–0043]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Reinstatement
of a Previously Approved Collection:
Drug Questionnaire (DEA–341)
DEPARTMENT OF JUSTICE
PO 00000
In
accordance with 21 CFR 1301.33(a), this
is notice that on August 6, 2020,
Nanosyn Inc., 3331 Industrial Drive,
Suite B, Santa Rosa, California 95403–
2062, applied to be registered as an bulk
manufacturer of the following basic
class(es) of controlled substances:
SUPPLEMENTARY INFORMATION:
Drug Enforcement Administration
BILLING CODE 7020–02–P
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 9, 2020. Such
persons may also file a written request
for a hearing on the application on or
before November 9, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
DATES:
DEPARTMENT OF JUSTICE
[FR Doc. 2020–19831 Filed 9–8–20; 8:45 am]
AGENCY:
Nanosyn Inc. has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled substances.
Refer to Supplemental Information
listed below for further drug
information.
SUMMARY:
Drug Enforcement
Administration, Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Drug Enforcement
Administration, Department of Justice
(DOJ), will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
SUMMARY:
E:\FR\FM\09SEN1.SGM
09SEN1
Agencies
[Federal Register Volume 85, Number 175 (Wednesday, September 9, 2020)]
[Notices]
[Page 55689]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-19868]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-704]
Bulk Manufacturer of Controlled Substances Application: Nanosyn
Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Nanosyn Inc. has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substances. Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before November 9,
2020. Such persons may also file a written request for a hearing on the
application on or before November 9, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on August 6, 2020, Nanosyn Inc., 3331 Industrial Drive,
Suite B, Santa Rosa, California 95403-2062, applied to be registered as
an bulk manufacturer of the following basic class(es) of controlled
substances:
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Oxymorphone............................ 9652 II
Fentanyl............................... 9801 II
------------------------------------------------------------------------
The company is a contract manufacturer. At the request of the
company's customers, it manufactures derivatives of controlled
substances in bulk form.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-19868 Filed 9-8-20; 8:45 am]
BILLING CODE P